Free tool
FAERS Monitor: Cinqair
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761033 or its brand name (Cinqair, Reslizumab). Reports on generic versions are filed under their own applications.
Reports
688
Serious
443
64% of reports
Hospitalization
142
Death reported
17
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea96
- asthma95
- incorrect dose administered88
- drug ineffective83
- hypertension73
- cough47
- headache43
- wheezing40
- fatigue39
- pneumonia33
- inappropriate schedule of product administration32
- oropharyngeal pain31
- myalgia30
- nausea29
- chest discomfort27
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 1 |
| 2014 | 1 |
| 2016 | 19 |
| 2017 | 90 |
| 2018 | 93 |
| 2019 | 58 |
| 2020 | 66 |
| 2021 | 72 |
| 2022 | 76 |
| 2023 | 45 |
| 2024 | 55 |
| 2025 | 73 |
| 2026 | 39 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,471 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| asthmaSignal | 95 | 25.7 | 21.3 | 2,243 |
| wheezingSignal | 40 | 20.6 | 15.3 | 729 |
| incorrect dose administeredSignal | 88 | 11.8 | 9.7 | 867 |
| hypertensionSignal | 73 | 10.5 | 8.5 | 627 |
| oropharyngeal painSignal | 31 | 10.2 | 7.3 | 250 |
| chest discomfortSignal | 27 | 8.1 | 5.6 | 161 |
| inappropriate schedule of product administrationSignal | 32 | 5.4 | 3.9 | 112 |
| myalgiaSignal | 30 | 5.4 | 3.8 | 104 |
| dyspnoeaSignal | 96 | 5.2 | 4.3 | 329 |
| coughSignal | 47 | 5.1 | 3.9 | 154 |
| pneumoniaSignal | 33 | 3.1 | 2.2 | 46 |
| headacheSignal | 43 | 2.1 | 1.6 | 24 |
| drug ineffective | 83 | 1.9 | 1.6 | 38 |
| fatigue | 39 | 1.5 | 1.1 | 7 |
| nausea | 29 | 1.1 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.